AML ARISING FROM ANTECEDENT HEMATOLOGIC DISORDER (AHD)

Clinical trials for AML ARISING FROM ANTECEDENT HEMATOLOGIC DISORDER (AHD) explained in plain language.

Never miss a new study

Get alerted when new AML ARISING FROM ANTECEDENT HEMATOLOGIC DISORDER (AHD) trials appear

Sign up with your email to follow new studies for AML ARISING FROM ANTECEDENT HEMATOLOGIC DISORDER (AHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug combo shows promise for Tough-to-Treat leukemia

Disease control Ongoing

This early-stage study tests whether adding AG-120 or AG-221 to standard chemotherapy is safe for people with a specific type of newly diagnosed acute myeloid leukemia (AML) that has an IDH1 or IDH2 mutation. About 153 adults will receive the study drug alongside standard inducti…

Matched conditions: AML ARISING FROM ANTECEDENT HEMATOLOGIC DISORDER (AHD)

Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control

Last updated May 26, 2026 12:11 UTC

AML ARISING FROM ANTECEDENT HEMATOLOGIC DISORDER (AHD)

Get alerted when new AML ARISING FROM ANTECEDENT HEMATOLOGIC DISORDER (AHD) trials appear

New drug combo shows promise for Tough-to-Treat leukemia